VIDEO: ‘Excellent’ anatomic, vision control seen with 4D-150 at 24 weeks
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carl Danzig, MD, discusses a subset analysis of high-need patients receiving 4D-150 for wet age-related macular degeneration in the PRISM trial.
The results showed “excellent anatomic and vision control” as well as “reduced injection burden in the high-dose arm” in patients who received 4D-150 (4D Molecular Therapeutics), according to Danzig, director of vitreoretinal services at Rand Eye Institute.
“Patients were getting one of two doses of 4D-150 or aflibercept, and in the higher dose, there was an 89% reduction of treatment burden, and 63% of patients were injection-free,” he said. “Furthermore, safety was excellent in this 24-week analysis.”
The company hopes to start a phase 3 trial in the beginning of 2025, he said.
Collapse
Danzig C. 24-week results from the randomized phase 2 dose expansion stage of PRISM trial evaluating 4D-150 in high need nAMD patients. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Read more about
Click Here to Manage Email Alerts